<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04439539</url>
  </required_header>
  <id_info>
    <org_study_id>CR108815</org_study_id>
    <secondary_id>73763989PAHPB2005</secondary_id>
    <secondary_id>2019-004978-26</secondary_id>
    <nct_id>NCT04439539</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-73763989 + JNJ-56136379 + Nucleos(t)Ide Analog (NA) Regimen With or Without Pegylated Interferon Alpha-2a (PegIFN-α2a) in Treatment-Naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection and Normal Alanine Aminotransferase (ALT)</brief_title>
  <official_title>A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Response-guided Treatment With JNJ-73763989 + JNJ-56136379 + Nucleos(t)Ide Analog Regimen With or Without Pegylated Interferon Alpha-2a in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection and Normal ALT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989
      + JNJ-56136379 + nucleos(t)ide analog (NA) with or without pegylated interferon alpha-2a
      (PegIFN-α2a).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B virus (HBV) is a small deoxyribonucleic acid virus that specifically infects the
      human liver. The acute phase of infection is either followed by an immune controlled state or
      progresses to chronic hepatitis B. The worldwide estimated prevalence of chronic HBV
      infection is about 292 million people affected. Hepatitis B surface antigen (HBsAg)
      seroclearance is currently considered to be associated with the most thorough suppression of
      HBV replication (termed functional cure). With current available NA treatment strategies,
      rate of HBsAg seroclearance remains very low (around 3 percent [%]) even under long-term
      treatment. Also, with the persistently high global prevalence of HBV-associated mortality,
      there is a medical need for more effective finite treatment options that lead to sustained
      HBsAg seroclearance. JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous
      injection designed to treat chronic HBV infection via a ribonucleic acid interference (RNAi)
      mechanism. JNJ-56136379 is an orally administered capsid assembly modulator (CAM) that is
      being developed for the treatment of chronic HBV infection. The aim of the study is to
      evaluate the efficacy of a treatment regimen of JNJ-73763989 + JNJ-56136379 + NA with or
      without PegIFN-α2a in participants with hepatitis B e antigen (HBeAg) positive chronic
      infection. The study will be conducted in 4 phases: a screening phase, an induction phase
      with flexible duration, a consolidation phase with or without PegIFN-α2a and a follow-up
      phase. Safety assessments will include Adverse Events (AEs), serious AEs of the study
      interventions, clinical laboratory tests, Electrocardiograms (ECGs), vital signs, and
      physical examinations.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 14, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Hepatitis B Surface Antigen (HBsAg) Seroclearance up to Week 96 (24 Weeks After Completion of all Study Interventions of Consolidation Phase) Without Restarting NA Treatment</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Percentage of participants with HBsAg seroclearance up to week 96 (24 weeks after completion of all study interventions of consolidation phase) without restarting nucleos(t)ide analog (NA) treatment will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious AEs</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Number of participants with clinically significant abnormalities in laboratory parameters (hematology, blood biochemistry, blood coagulation, urinalysis, urine chemistry, and renal biomarkers) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECGs)</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Number of participants with clinically significant abnormalities in electrocardiogram (ECGs) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Vital Signs</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Number of participants with clinically significant abnormalities in vital signs (systolic and diastolic blood pressure, pulse rate, and body temperature) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Physical Examination</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Number of participants with clinically significant abnormalities in physical examination will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who met Response Guided Treatment (RGT) Criteria up to Week 60</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Percentage of participants who met RGT criteria up to Week 60 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Meet Response Guided Treatment (RGT) Criteria</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Time to meet RGT criteria up to week 60 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting NA Treatment Completion Criteria at the end of Consolidation Phase</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants meeting NA treatment completion criteria at the end of consolidation phase will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Hepatitis B Surface Antigen (HBsAg) Seroclearance</measure>
    <time_frame>48 weeks after stopping all study interventions of the consolidation phase and without restarting NA treatment during follow up phase (Up to Week 126)</time_frame>
    <description>Percentage of participants with HBsAg Seroclearance will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBV DNA less than (&lt;) Lower Limit of Quantification (LLOQ)</measure>
    <time_frame>48 weeks after stopping all study interventions of the consolidation phase and without restarting NA treatment during follow up phase (Up to Week 126)</time_frame>
    <description>Percentage of participants with hepatitis B virus (HBV) deoxyribonucleic acid (DNA) &lt;LLOQ will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Flares</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Number of participants with flares (virologic, biochemical and clinical flares) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring NA Re-treatment</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Percentage of participants requiring NA re-treatment based on failure in NA treatment completion criteria will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with (Sustained) Reduction, Suppression, and/or Seroclearance</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Percentage of participants with (sustained) reduction, suppression, and/or seroclearance considering single and multiple markers (such as hepatitis B surface antigen [HBsAg], hepatitis B e antigen [HBeAg], HBV DNA and alanine aminotransferase [ALT]) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Hepatitis B Surface Antigen (HBsAg) and Hepatitis B e Antigen (HBeAg) Seroconversion</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Percentage of participants with HBsAg and HBeAg seroconversion will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Hepatitis B Surface Antigen (HBsAg) Seroclearance</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Time to achieve HBsAg seroclearance will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Hepatitis B e Antigen (HBeAg) Seroclearance</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Time to achieve hepatitis B e antigen (HBeAg) seroclearance will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) &lt;LLOQ</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Time to achieve HBV DNA &lt;LLOQ will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Hepatitis B e Antigen (HBeAg), Hepatitis B Surface Antigen (HBsAg), and Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Percentage of participants with HBeAg, HBsAg, and HBV DNA Levels will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hepatitis B e Antigen (HBeAg)</measure>
    <time_frame>Baseline and Week 126</time_frame>
    <description>Change from baseline in HBeAg will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hepatitis B Surface Antigen (HBsAg)</measure>
    <time_frame>Baseline and Week 126</time_frame>
    <description>Change from baseline in HBsAg will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels</measure>
    <time_frame>Baseline and Week 126</time_frame>
    <description>Change from baseline in HBV DNA levels will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Virologic Breakthrough</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Percentage of participants with virologic breakthrough (defined as confirmed on-treatment HBV DNA increase by greater than (&gt;) 1 log10 IU/mL from nadir level or confirmed on treatment level &gt;200 IU/mL in participants who had HBV DNA level below &lt;LLOQ of the HBV DNA assay) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Reach Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Undetectability After Re-start of NA Treatment During Follow-up</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Percentage of participants who reach HBV DNA undetectability after re-start of NA treatment during follow-up will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Up to Day 421 postdose</time_frame>
    <description>Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours [AUC (0- 24 hours)]</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>AUC (0- 24 hours) is the area under the plasma concentration-time curve from time zero to 24 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>JNJ-73763989 + JNJ-56136379 + NA (with PegIFN-α2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with nucleos(t)ide analog (NA) (tenofovir disoproxil tablets orally) treatment. During initiating the consolidation phase, participants will be randomized to receive pegylated interferon alpha-2a (PegIFN-α2a subcutaneously. According to predefined criteria NA treatment may be continued during the follow up (FU) phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-73763989 + JNJ-56136379 + NA (without PegIFN-α2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with nucleos(t)ide analog (NA) (tenofovir disoproxil tablets orally) treatment. During initiating the consolidation phase, participants will be randomized not to receive pegylated interferon alpha-2a (PegIFN-α2a subcutaneously. According to predefined criteria NA treatment may be continued during the follow up (FU) phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-73763989</intervention_name>
    <description>JNJ-73763989 injection will be administered subcutaneously.</description>
    <arm_group_label>JNJ-73763989 + JNJ-56136379 + NA (with PegIFN-α2a)</arm_group_label>
    <arm_group_label>JNJ-73763989 + JNJ-56136379 + NA (without PegIFN-α2a)</arm_group_label>
    <other_name>JNJ-3989</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-56136379</intervention_name>
    <description>JNJ-56136379 tablets will be administered orally.</description>
    <arm_group_label>JNJ-73763989 + JNJ-56136379 + NA (with PegIFN-α2a)</arm_group_label>
    <arm_group_label>JNJ-73763989 + JNJ-56136379 + NA (without PegIFN-α2a)</arm_group_label>
    <other_name>JNJ-6379</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIFN-α2a</intervention_name>
    <description>PegIFN-α2a injection will be administered subcutaneously.</description>
    <arm_group_label>JNJ-73763989 + JNJ-56136379 + NA (with PegIFN-α2a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <description>Tenofovir disoproxil film-coated tablet will be administered orally.</description>
    <arm_group_label>JNJ-73763989 + JNJ-56136379 + NA (with PegIFN-α2a)</arm_group_label>
    <arm_group_label>JNJ-73763989 + JNJ-56136379 + NA (without PegIFN-α2a)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically stable based on physical examination, medical history, vital signs,
             laboratory values, and 12-lead Electrocardiogram (ECG) at screening

          -  Chronic hepatitis B virus (HBV) infection with documentation at least 6 months prior
             to screening

          -  hepatitis B virus (HBV) deoxyribonucleic acid (DNA) greater than or equal to (&gt;=)
             20,000 international units per milliliter (IU/mL)

          -  Body mass index (BMI) between 18.0 and 35.0 kilogram per meter square (kg/m^2),
             extremes included

          -  Liver fibrosis stage 0-2 (Metavir) or Fibroscan less than or equal to (&lt;=) 9
             Kilopascal (kPa) at screening

        Exclusion Criteria:

          -  Evidence of infection with hepatitis A, C, D or E virus infection or evidence of human
             immunodeficiency, virus type 1 (HIV-1) or HIV-2 infection at screening

          -  History or evidence of clinical signs or symptoms of hepatic decompensation, including
             but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal
             varices

          -  Evidence of liver disease of non-HBV etiology

          -  Participants with a history of malignancy within 5 years before screening

          -  Participants who had or planned major surgery, (example, requiring general anesthesia)
             or who have received an organ transplant

          -  Contraindications to the use of PegIFN-α2a
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruane Clinical Research Group Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Center For Liver Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute Northwest</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Research Institute (G.I.R.I.)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre Society</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>ON M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Johann Wolfgang Goethe- Universität Frankfurt Medizinische Klinik 1</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musashino Red Cross Hospital</name>
      <address>
        <city>Musashino</city>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ural State Medical University</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital #1</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irkutsk State Medical University</name>
      <address>
        <city>Irkutsk</city>
        <zip>664003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Infectious Hospital n.a. AF Agafonov</name>
      <address>
        <city>Kazan</city>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Center For AIDS And Infectious Diseases Treatment And Prophylaxis</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of the Modern Medicine</name>
      <address>
        <city>Moscow</city>
        <zip>121170</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE Moscow State Medical and Dentistry University n.a. A. I. Evdokimov of the MoH of the RF</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg City Center for AIDS and Infectious Diseases Treatment and Prophylaxis</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBMEI HPE Military Medical Academy n.a. S.M. Kirov of the MoD of the RF</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Infectious Diseases Hospital n. a. S.P. Botkin</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Company 'Hepatolog' Ltd</name>
      <address>
        <city>Samara</city>
        <zip>443045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol State Medical University</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Tiachung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>6230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umraniye Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34764</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical of Faculty, Department of Gastroenterology</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konya Selcuk University Medical Faculty</name>
      <address>
        <city>Konya</city>
        <zip>42250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem Mehmet Ali Aydinlar University</name>
      <address>
        <city>Kucukcekmece</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik University Medical Faculty</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grahame Hayton Unit</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

